Christine Fischette

Christine Fischette, Ph.D. is a seasoned professional in the fields of biotechnology and corporate strategy, currently serving as an Advisory Board Member at Concord Engineering Group, Inc. since September 2022 and as Director at Antag Therapeutics since July 2021, focusing on therapeutic peptides for dietary-related metabolic diseases. In addition to these roles, Christine has been the CEO of BioLinkUp, LLC since April 2010, leading business development initiatives. Previous experience includes positions as Executive Director at Torreya Partners, Senior Advisor at Griffin Securities, Inc., and President at Enzo Therapeutics. Christine's notable tenure at Novartis as Head of Negotiation in Global Business Development and Licensing, along with significant roles at Pfizer and Hoffman-La Roche, complements a robust academic foundation with a Ph.D. in Physiology and a Bachelor's degree in Biology Education from Rutgers University.